Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
Hemophilia A is characterized by a deficiency of clotting factor VIII (FVIII) requiring lifelong prophylactic treatment, typically with recombinant FVIII. In recent years, drugs with extended half-lives have become available, including damoctocog alfa pegol (Bayer S.p.A.). The clinical efficacy and...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2023-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|